Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leuprolide + tamoxifen + trastuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intramuscular, Oral, Intravenous
01
Overview
A combination therapy consisting of leuprolide (a luteinizing hormone-releasing hormone analog), tamoxifen (a selective estrogen receptor modulator), and trastuzumab (a HER2-targeted monoclonal antibody). This regimen is used primarily for the treatment of hormone receptor-positive (HR+) and HER2-positive breast cancer in premenopausal women. The combination works through multiple mechanisms: leuprolide suppresses ovarian function and reduces estrogen production, tamoxifen blocks estrogen receptors in breast tissue, and trastuzumab targets the HER2 protein overexpressed in certain breast cancers.
02
Targets
ER (Estrogen receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on leuprolide + tamoxifen + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leuprolide + tamoxifen + trastuzumab.